Reports Q4 revenue $13.8B, consensus $13.67B.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Merck’s Keytruda approved by FDA for non-small cell lung cancer treatment
- Another Feather on Merck’s Cap: Keytruda’s NSCLC Treatment Gets Another Indication
- Merck Animal Health announces FDA approval for Bravecto Chews for Dogs
- Merck to stop Phase 3 KEYNOTE-991 trial